Gary Yiu

Gary Yiu has extensive work experience in the field of immune medicines and pharmaceutical research. Gary is currently employed as a Principal Scientist at Repertoire Immune Medicines, where they lead the Antigen Processing and Presentation team. In this role, Gary has been responsible for generating and validating over 50 specific antigen presenting cell lines, each expressing a single HLA class I or class II protein. Gary has also collaborated with functional teams and bioinformatics groups to create a database of identified HLA-restricted peptides. Additionally, Gary has supervised the design of tandem minigenes and full-length proteins to identify peptide epitopes of selected antigens. Gary has experience in isolating primary immune cells and expanding them into dendritic cells and peptide epitope-specific T cells. Gary's role also involves coordinating collaborative efforts across the organization and managing the research of junior scientists.

Prior to their current position, Gary worked as a Principal Scientist at Cogen Immune Medicines from 2017 to 2020. Gary also has research experience at Alexion Pharmaceuticals, Synageva BioPharma Corp., AstraZeneca R&D Boston, Beth Israel Deaconess Medical Center, and Brigham and Women's Hospital. In these roles, Gary has held various research and scientist positions, contributing to the field of immune medicines and molecular engineering.

Gary Yiu holds a Doctor of Philosophy (Ph.D.) in Cell & Molecular Biology from Tufts University. Prior to that, they completed an M.Phil. in Anatomical and Cellular Pathology as well as a B.Sc. (Hons.) in Biology & Biochemistry from The Chinese University of Hong Kong.